ACRO’s RBQM report shows how clinical trials were forced to shift to remote monitoring during the COVID-19 pandemic, and highlights why the industry shouldn’t turn back.
Risk-based monitoring (RBM) is a powerful tool for efficiently ensuring patient safety and data integrity in a clinical trial, enhancing overall trial quality. To better understand the RBM implementation landscape across the industry, ACRO conducted a landscape survey of RBM implementation across 6,513 clinical trials that were ongoing in 2019 and compiled the information in a comprehensive report.